In COVID-19, an ACE1/ACE2 imbalance occurs, due to the binding of SARS-CoV2 to ACE2, reducing ACE2-mediated conversion of angiotensin II to angiotensin peptides that physiologically counteract pathophysiological effects of ACE1-generated angiotensin II [42]. This evidence concerns the gene ACE2 and COVID-19.